

PATENT

Case Docket No. TOYAM77.001AUS
Date: July 18, 2002

JUL 23 2002

Applicant(s) : Imai, et al.
App. No. : 09/963,316
Filed : September 25, 2001
For : USES OF ANTI-CX3CR1 ANTIBODY,
ANTI-FRACTALKINE ANTIBODY AND
FRACTALKINE
Group Art Unit : Unknown

I hereby certify that this correspondence and all marked
attachments are being deposited with the United States Postal
Service as first class mail in an envelope addressed to: United
States Patent and Trademark Office, P.O. Box 2327, Arlington,
VA 22202, on

July 18, 2002

Che S. Chereskin
Che Swyden Chereskin, Ph.D. Reg. No. 41,466

TRANSMITTAL LETTER

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202
ATTENTION: BOX SEQUENCE

Dear Sir:

In response to the Notice to Comply with Requirements for Patent Applications containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, which was mailed by the Office on June 6, 2002, enclosed are:

- Sequence Submission Statement.
- Substitute Sequence Listing in computer readable form (diskette).
- Paper copy of Substitute Sequence Listing in 1 page.
- Copy of Notice to Comply.
- Return prepaid postcard.
- The Commissioner is hereby authorized to charge any additional fees which may be required, now or in the future, or credit any overpayment, to Account No. 11-1410.

Che S. Chereskin
Che Swyden Chereskin, Ph.D.
Registration No. 41,466
Agent of Record



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/963,316	09/25/2001	Toshio Imai	TOYAM77.001AUS

CONFIRMATION NO. 1352

20995
KNOBBE MARTENS OLSON & BEAR LLP
620 NEWPORT CENTER DRIVE
SIXTEENTH FLOOR
NEWPORT BEACH, CA 92660

FORMALITIES LETTER



'OC000000008246595'

Date Mailed: 06/06/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

nlw
Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 -COPY TO BE RETURNED WITH RESPONSE